Published in PLoS One on February 09, 2010
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One (2010) 1.93
The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell (2014) 1.65
Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47
The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell (2013) 1.36
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res (2012) 1.32
Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol (2010) 1.29
The biology of head and neck cancer stem cells. Oral Oncol (2011) 1.25
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
High SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS One (2013) 1.13
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer (2011) 1.12
Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One (2012) 1.10
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest (2014) 1.10
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PLoS One (2012) 1.06
Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol (2013) 1.04
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun (2014) 1.02
SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study. Exp Dermatol (2011) 1.01
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol (2011) 1.00
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00
The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.96
New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res (2012) 0.93
Expression of Bmi1, FoxF1, Nanog, and γ-catenin in relation to hedgehog signaling pathway in human non-small-cell lung cancer. Lung (2013) 0.91
Increased Sox2 copy number in lung squamous cell carcinomas. Exp Ther Med (2011) 0.90
Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers. Cancer Epidemiol Biomarkers Prev (2013) 0.89
SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness. J Cancer Res Clin Oncol (2014) 0.87
Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma. Cancer Cell (2016) 0.86
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma. Cancer Res (2014) 0.86
Overexpression of SOX2 Is Associated with Better Overall Survival in Squamous Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy. Cancer Res Treat (2015) 0.84
SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci Rep (2016) 0.84
True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. PLoS One (2012) 0.83
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (2014) 0.83
SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. Onco Targets Ther (2015) 0.83
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer (2014) 0.83
Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer. PLoS One (2013) 0.82
An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clin Cancer Res (2015) 0.82
SOX2 inhibits metastasis in gastric cancer. J Cancer Res Clin Oncol (2016) 0.82
Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. Oncotarget (2015) 0.81
The role of Sox genes in lung morphogenesis and cancer. Int J Mol Sci (2012) 0.81
Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget (2016) 0.80
CAFET algorithm reveals Wnt/PCP signature in lung squamous cell carcinoma. PLoS One (2011) 0.79
An evaluation of SOX2 and hTERC gene amplifications as screening markers in oral and oropharyngeal squamous cell carcinomas. Mol Cytogenet (2014) 0.79
FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway. Oncotarget (2016) 0.78
The role of SOX2 in small cell lung cancer, lung adenocarcinoma and squamous cell carcinoma of the lung. Transl Lung Cancer Res (2013) 0.78
The impact of the Cancer Genome Atlas on lung cancer. Transl Res (2015) 0.77
Role of SOX2 in the etiology of embryonal carcinoma, based on analysis of the NCCIT and NT2 cell lines. PLoS One (2014) 0.77
The role of SOX-2 on the survival of patients with non-small cell lung cancer. J Thorac Dis (2015) 0.76
The chromosome 3q26 OncCassette: A multigenic driver of human cancer. Adv Biol Regul (2015) 0.76
DNA copy number gains in malignant pleural mesothelioma. Oncol Lett (2015) 0.75
Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer. BMC Cancer (2016) 0.75
The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy. Biomed Res Int (2016) 0.75
The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nat Commun (2016) 0.75
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. PLoS Biol (2016) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res (2003) 52.74
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Lung cancer. N Engl J Med (2008) 13.49
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development (1997) 5.09
Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev (1998) 4.58
Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol (2005) 4.52
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Multiple roles for Sox2 in the developing and adult mouse trachea. Development (2009) 2.62
K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res (1996) 2.29
Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol (2008) 2.06
Lung cancer preneoplasia. Annu Rev Pathol (2006) 2.04
Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.50
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res (Phila) (2008) 1.44
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell (2009) 6.16
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst (2003) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell (2012) 4.37
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature (2012) 3.44
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
Management of primary pulmonary artery sarcomas. Ann Thorac Surg (2009) 3.37
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene (2002) 2.92
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A (2010) 2.69
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature (2011) 2.58
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell (2010) 2.50
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat Biotechnol (2013) 2.44
A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol (2007) 2.43
A potent dauer pheromone component in Caenorhabditis elegans that acts synergistically with other components. Proc Natl Acad Sci U S A (2008) 2.35
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34
The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol (2011) 2.31
Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst (2003) 2.31
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res (2006) 2.31
Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol (2003) 2.30